http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-105164160-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-565 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-507 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-32 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2863 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-40 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-26 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-3955 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39558 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-46 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-13 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 |
| filingDate | 2014-05-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2018-11-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2018-11-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-105164160-B |
| titleOfInvention | Antibodies that specifically bind to HER2 |
| abstract | The present invention relates to novel HER2 antibodies for combined administration for the prevention or treatment of cancer. The antibody of the present invention specifically binds to HER2 overexpressed in cancer cells (especially breast cancer cells and gastric cancer cells), and binds to an epitope different from that bound by trastuzumab. The antibodies of the present invention have unique sequences because they have very low homology compared to the CDR sequences of known HER2-targeting antibodies. When administered in combination with trastuzumab, the antibody of the present invention kills cancer cells with significantly improved cancer cell killing ability, and thus is very useful for the prevention or treatment of cancer (especially breast cancer and gastric cancer). Without wishing to be bound by theory, it is believed that the apparent efficacy of the co-administered antibodies of the invention is due to the binding of the antibodies of the invention to an epitope of HER2 distinct from the epitope bound by trastuzumab, and thus synergistically inhibits HER2 with trastuzumab . |
| priorityDate | 2013-05-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 741.